Reviews
Meta-Analysis of First-Line Regimens in Metastatic Clear Cell Renal Cell Carcinoma
McGrath et alUrologic oncology

A network meta-analysis evaluated first-line immune checkpoint inhibitor (ICI)-based combination regimens for metastatic clear-cell renal cell carcinoma (mccRCC), comparing conventional hazard ratio (HR)-based analyses against difference in restricted mean survival time (dRMST). The analysis also introduced a framework contextualizing survival outcomes alongside high-dose corticosteroid use, grade ≥3 treatment-related adverse events (TRAEs), and drug-acquisition costs.
Data were synthesized from five phase III clinical trials comparing ICI combinations with sunitinib. Published trial-level HRs informed HR-based models, and reconstructed individual patient data were used to estimate dRMST for overall survival (OS) across 40 to 64 months and progression-free survival (PFS) across 24 to 48 months using frequentist common-effect models.
All regimens significantly improved dRMST compared with sunitinib for OS and PFS, with the exception of avelumab plus axitinib for OS and nivolumab plus ipilimumab for PFS. Concordance between HR and dRMST rankings was greater for PFS across horizons and increased over time for both endpoints. For OS, nivolumab plus ipilimumab ranked first by HR, whereas nivolumab plus cabozantinib ranked first at every evaluated dRMST horizon. Lenvatinib plus pembrolizumab ranked highest for PFS under both approaches. Additionally, dRMST provided clearer temporal separation and distinguished early versus later accumulation of benefit, while nivolumab plus ipilimumab had the lowest grade ≥3 TRAE risk and the lowest drug-acquisition cost per RMST-month gained.
Key Takeaways
- For overall survival, nivolumab plus cabozantinib ranked first across all difference in restricted mean survival time (dRMST) horizons, whereas nivolumab plus ipilimumab ranked first by hazard ratio.
- Lenvatinib plus pembrolizumab ranked first for progression-free survival under both hazard ratio and dRMST approaches, with all regimens significantly improving dRMST versus sunitinib for overall survival and progression-free survival except avelumab plus axitinib and nivolumab plus ipilimumab, respectively.
- Nivolumab plus ipilimumab had the lowest grade ≥3 treatment-related adverse event risk and the lowest incremental drug-acquisition cost per RMST-month gained.
Read the original sourceUrologic oncology
